We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.34B
AUM Growth
+$140M
(+6.4%)
Cap. Flow
+$87.9M
Cap. Flow
% of AUM
3.75%
Top 10 Holdings %
Top 10 Hldgs %
23.56%
Holding
168
New
20
Increased
60
Reduced
15
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$65.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$38.6M |
| 3 |
HCA Healthcare
HCA
|
+$36.9M |
| 4 |
Cencora
COR
|
+$28.3M |
| 5 |
DaVita
DVA
|
+$24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AAAP
Advanced Accelerator Applications S.A.
AAAP
|
+$67.4M |
| 2 |
Cigna
CI
|
+$65.2M |
| 3 |
Merck
MRK
|
+$47.9M |
| 4 |
Johnson & Johnson
JNJ
|
+$27.9M |
| 5 |
Willis Towers Watson
WTW
|
+$18.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.66% |
| 2 | Financials | 1.72% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$382B
| $104M | 4.45% |
487,500
+500
| +0.1% | +$114K |
|
2
Intuitive Surgical
ISRG
$127B
| $59.4M | 2.53% |
431,700
| – | – |
|
|
3
AbbVie
ABBV
$465B
| $56.8M | 2.42% |
+600,000
| New | +$65.9M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $54.1M | 2.31% |
485,000
+5,000
| +1% | +$598K |
|
5
Neurocrine Biosciences
NBIX
$18.2B
| $50.3M | 2.14% |
606,200
+120,200
| +25% | +$10.2M |
|
6
Acadia Healthcare
ACHC
$2.52B
| $49.1M | 2.1% |
1,253,500
| – | – |
|
7
Collegium Pharmaceutical
COLL
$1.18B
| $49.1M | 2.09% |
1,920,000
+34,271
| +2% | +$817K |
|
8
Molina Healthcare
MOH
$10.4B
| $46.8M | 1.99% |
576,000
+9,000
| +2% | +$724K |
|
|
ONCE
9
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $41.5M | 1.77% |
623,500
+8,500
| +1% | +$491K |
|
|
10
Bristol-Myers Squibb
BMY
$129B
| $41.1M | 1.75% |
650,000
+600,000
| +1,200% | +$38.6M |
|
|
GWPH
11
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $40.6M | 1.73% |
360,000
+6,000
| +2% | +$754K |
|
|
AET
12
DELISTED
Aetna Inc
AET
| $40.4M | 1.72% |
239,000
| – | – |
|
13
Madrigal Pharmaceuticals
MDGL
$12.6B
| $38M | 1.62% |
325,500
-16,500
| -5% | -$2.04M |
|
|
ONC
14
BeOne Medicines Ltd
ONC
$33.9B
| $37.2M | 1.59% |
221,250
-44,750
| -17% | -$6.06M |
|
|
15
HCA Healthcare
HCA
$90.6B
| $36.9M | 1.57% |
+380,000
| New | +$36.9M |
|
|
LOXO
16
DELISTED
Loxo Oncology, Inc
LOXO
| $36.5M | 1.56% |
316,500
+6,500
| +2% | +$691K |
|
|
RDUS
17
DELISTED
Radius Health, Inc.
RDUS
| $35.9M | 1.53% |
1,000,000
+57,000
| +6% | +$2.06M |
|
18
Pacira BioSciences
PCRX
$1.04B
| $35M | 1.49% |
1,125,000
+18,300
| +2% | +$652K |
|
|
PRAH
19
DELISTED
PRA Health Sciences, Inc.
PRAH
| $32.8M | 1.4% |
395,000
-82,500
| -17% | -$7.33M |
|
|
TSRO
20
DELISTED
TESARO, Inc.
TSRO
| $32.7M | 1.4% |
573,000
+24,500
| +4% | +$1.58M |
|
21
iRhythm Holdings
IRTC
$4.02B
| $30.1M | 1.28% |
477,500
+71,500
| +18% | +$4.43M |
|
22
Vertex Pharmaceuticals
VRTX
$123B
| $29.5M | 1.26% |
181,000
+9,750
| +6% | +$1.59M |
|
23
Stryker
SYK
$135B
| $28.6M | 1.22% |
178,000
+51,500
| +41% | +$8.3M |
|
24
Penumbra
PEN
$12.6B
| $28.1M | 1.2% |
243,000
-67,500
| -22% | -$6.97M |
|
25
Puma Biotechnology
PBYI
$398M
| $28.1M | 1.2% |
412,900
+39,400
| +11% | +$2.95M |
|
Similar funds
AAM
SGI
ACM
BCM
ISS
PP
FDP
GAM
Rock Springs Capital Management's Q1 2018 Portfolio in Review
As of Q1 2018, Rock Springs Capital Management held 168 positions worth $2.34B, up 6.4% from $2.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Rock Springs Capital Management deployed $87.9M of net new capital in Q1 2018, opening 20 new positions and adding to 60 existing holdings. Its largest new stake was AbbVie: 600,000 shares worth $56.8M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was PRA Health Sciences, Inc., an estimated $7.33M trimmed.
- Rock Springs Capital Management's largest Q1 2018 buy was AbbVie: 600,000 shares worth $56.8M.
- Rock Springs Capital Management added most to Bristol-Myers Squibb in Q1 2018, an estimated $38.6M increase.
- Rock Springs Capital Management's biggest Q1 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $7.33M.
- Rock Springs Capital Management fully exited Advanced Accelerator Applications S.A. in Q1 2018, selling an estimated $67.4M.
- Rock Springs Capital Management's ten largest holdings make up 24% of its $2.34B portfolio in Q1 2018.
- Rock Springs Capital Management opened 20 new positions and closed 19 in Q1 2018.
- Rock Springs Capital Management's portfolio value rose 6.4% quarter-over-quarter to $2.34B.
Based on Rock Springs Capital Management's 13F filing for Q1 2018, filed 15 May 2018.